Considering the diverse MR, immune evasion strategies, and drug resistance mechanisms exhibited by different cancers, it is crucial to identify a range of cancer-specific genes for biomarker screening (Wamsley et al., 2023). The gene discussed is NR3C2; the disease is cancer.